HUP0105282A3 - Acetylenic sulfonamide thiol tace inhibitors process for their preparation and pharmaceutical compositions containing the same - Google Patents
Acetylenic sulfonamide thiol tace inhibitors process for their preparation and pharmaceutical compositions containing the sameInfo
- Publication number
- HUP0105282A3 HUP0105282A3 HU0105282A HUP0105282A HUP0105282A3 HU P0105282 A3 HUP0105282 A3 HU P0105282A3 HU 0105282 A HU0105282 A HU 0105282A HU P0105282 A HUP0105282 A HU P0105282A HU P0105282 A3 HUP0105282 A3 HU P0105282A3
- Authority
- HU
- Hungary
- Prior art keywords
- preparation
- pharmaceutical compositions
- same
- compositions containing
- tace inhibitors
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- -1 sulfonamide thiol Chemical class 0.000 title 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23839399A | 1999-01-27 | 1999-01-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0105282A2 HUP0105282A2 (hu) | 2002-05-29 |
HUP0105282A3 true HUP0105282A3 (en) | 2005-04-28 |
Family
ID=22897697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0105282A HUP0105282A3 (en) | 1999-01-27 | 2000-01-27 | Acetylenic sulfonamide thiol tace inhibitors process for their preparation and pharmaceutical compositions containing the same |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1149074B1 (hu) |
JP (1) | JP2002535386A (hu) |
KR (1) | KR20010101691A (hu) |
CN (1) | CN1224612C (hu) |
AT (1) | ATE280152T1 (hu) |
AU (1) | AU766192B2 (hu) |
BR (1) | BR0007727A (hu) |
CA (1) | CA2356480A1 (hu) |
CZ (1) | CZ20012545A3 (hu) |
DE (1) | DE60015079T2 (hu) |
DK (1) | DK1149074T3 (hu) |
EA (1) | EA200100811A1 (hu) |
ES (1) | ES2230064T3 (hu) |
HK (1) | HK1038915A1 (hu) |
HU (1) | HUP0105282A3 (hu) |
IL (1) | IL144347A0 (hu) |
NO (1) | NO20013638L (hu) |
NZ (1) | NZ512306A (hu) |
PL (1) | PL350420A1 (hu) |
WO (1) | WO2000044716A1 (hu) |
ZA (1) | ZA200105069B (hu) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003033477A1 (en) * | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkynlated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitor |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
DE60232276D1 (de) | 2001-12-20 | 2009-06-18 | Bristol Myers Squibb Co | Alpha-(n-sulfonamid)acetamidderivate als beta-amyloidinhibitoren |
US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
US8084477B2 (en) | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
US8093276B2 (en) | 2007-10-31 | 2012-01-10 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
US8044077B2 (en) | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
US7977362B2 (en) | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2194209T3 (es) * | 1996-07-22 | 2003-11-16 | Monsanto Co | Inhibidores de metaloproteasa de tiol sulfona. |
NZ333825A (en) * | 1996-07-22 | 2000-10-27 | Monsanto Co | Metalloprotease inhibitors particularly MMP-13 |
-
2000
- 2000-01-27 CZ CZ20012545A patent/CZ20012545A3/cs unknown
- 2000-01-27 AU AU27417/00A patent/AU766192B2/en not_active Ceased
- 2000-01-27 NZ NZ512306A patent/NZ512306A/en unknown
- 2000-01-27 JP JP2000595972A patent/JP2002535386A/ja active Pending
- 2000-01-27 HU HU0105282A patent/HUP0105282A3/hu unknown
- 2000-01-27 EA EA200100811A patent/EA200100811A1/ru unknown
- 2000-01-27 EP EP00905787A patent/EP1149074B1/en not_active Expired - Lifetime
- 2000-01-27 PL PL00350420A patent/PL350420A1/xx not_active Application Discontinuation
- 2000-01-27 KR KR1020017009365A patent/KR20010101691A/ko not_active Application Discontinuation
- 2000-01-27 DE DE60015079T patent/DE60015079T2/de not_active Expired - Fee Related
- 2000-01-27 CA CA002356480A patent/CA2356480A1/en not_active Abandoned
- 2000-01-27 DK DK00905787T patent/DK1149074T3/da active
- 2000-01-27 ES ES00905787T patent/ES2230064T3/es not_active Expired - Lifetime
- 2000-01-27 AT AT00905787T patent/ATE280152T1/de not_active IP Right Cessation
- 2000-01-27 WO PCT/US2000/002143 patent/WO2000044716A1/en not_active Application Discontinuation
- 2000-01-27 CN CNB008030286A patent/CN1224612C/zh not_active Expired - Fee Related
- 2000-01-27 BR BR0007727-5A patent/BR0007727A/pt not_active IP Right Cessation
- 2000-01-27 IL IL14434700A patent/IL144347A0/xx unknown
-
2001
- 2001-06-20 ZA ZA200105069A patent/ZA200105069B/en unknown
- 2001-07-24 NO NO20013638A patent/NO20013638L/no not_active Application Discontinuation
-
2002
- 2002-01-18 HK HK02100417.3A patent/HK1038915A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0105282A2 (hu) | 2002-05-29 |
HK1038915A1 (zh) | 2002-04-04 |
EP1149074A1 (en) | 2001-10-31 |
BR0007727A (pt) | 2001-10-30 |
AU766192B2 (en) | 2003-10-09 |
CA2356480A1 (en) | 2000-08-03 |
DK1149074T3 (da) | 2005-01-10 |
NZ512306A (en) | 2003-10-31 |
WO2000044716A1 (en) | 2000-08-03 |
NO20013638D0 (no) | 2001-07-24 |
KR20010101691A (ko) | 2001-11-14 |
DE60015079T2 (de) | 2005-03-03 |
AU2741700A (en) | 2000-08-18 |
NO20013638L (no) | 2001-07-24 |
CN1337947A (zh) | 2002-02-27 |
PL350420A1 (en) | 2002-12-16 |
CZ20012545A3 (cs) | 2002-04-17 |
ZA200105069B (en) | 2002-09-20 |
ES2230064T3 (es) | 2005-05-01 |
EA200100811A1 (ru) | 2002-12-26 |
EP1149074B1 (en) | 2004-10-20 |
JP2002535386A (ja) | 2002-10-22 |
IL144347A0 (en) | 2002-05-23 |
ATE280152T1 (de) | 2004-11-15 |
DE60015079D1 (de) | 2004-11-25 |
CN1224612C (zh) | 2005-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0103344A3 (en) | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp), process for their preparation and pharmaceutical compositions containing them | |
HUP0203122A3 (en) | Fab i inhibitors, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0201376A2 (en) | Thiazoloderivatives and pharmaceutical compositions containing them and process for preparation the compounds | |
HUP0103452A3 (en) | Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors and pharmaceutical compositions containing the compounds | |
HUP0302922A3 (en) | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation and pharmaceutical compositions containing them | |
IL202633A0 (en) | Sulfonamide derivatives and pharmaceutical compositions containing the same | |
HUP0400974A3 (en) | Peptide-based compounds and pharmaceutical compositions containing them | |
HUP0300544A3 (en) | Pharmaceutical compositions containing integrin expression inhibitors | |
HUP0101176A3 (en) | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them | |
HUP0402263A3 (en) | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors, process for their preparation and pharmaceutical compositions containing them | |
HUP0204496A3 (en) | Novel piperidine compounds and pharmaceutical compositions containing the same and process for preparation the same | |
HUP0104768A3 (en) | 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same | |
HUP0303325A3 (en) | Pharmaceutical salts and pharmaceutical compositions containing them | |
HUP0200347A3 (en) | N-cyanomethylamides as protease inhibitors, pharmaceutical compositions containing them and their use | |
HUP0302485A3 (en) | Arylmethylamine derivatives for use as tryptase inhibitors and pharmaceutical compositions containing them | |
HUP0200355A3 (en) | 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use | |
HUP0203378A3 (en) | Pharmaceutical compounds and pharmaceutical compositions containing them | |
HUP0103851A3 (en) | Factor viia inhibitors, process for their preparation, their use and pharmaceutical compositions comprising thereof | |
HUP0101281A3 (en) | Diphenyl-piperidine butanamides as glycine transport inhibitors, process for producing them, use of them for producing medicaments and the pharmaceutical compositions containing them | |
IL138725A0 (en) | Sulfonamide derivatives and pharmaceutical compositions containing the same | |
HUP0105160A3 (en) | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-betha-cyclodextrin or 2-hydroxypropyl-betha-cyclodextrin and method for its preparation and pharmaceutical compositions containing them | |
EP1311477A4 (en) | NEW THIOCARBAMIDIC ACID DERIVATIVES AND MEDICAMENTS CONTAINING THEM | |
HUP0400040A2 (hu) | Szulfonamidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP9803040A3 (en) | Thiazole derivatives, process for the preparation thereof, use thereof and pharmaceutical compositions containing them | |
HUP0202934A3 (en) | Arylsulfonamido-substituted hydroxamic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof |